Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 102-112

  Merrick, John ^a   Lane, Brian ^a   Sebree, Terri ^b   Yaksh, Tony ^c   O'Neill, Carol ^b   Banks, Stan L ^b  

^a Pace Analytical Life Sciences   (United States)

^b Zynerba Pharmaceuticals Inc   (United States)

^c University of California   (United States)

Author keywords

cannabidiol; degredation; drug discovery; gastric fluid; kinetics; THC

Indexed keywords

CANNABIDIOL; DELTA8 TETRAHYDROCANNABINOL; DODECYL SULFATE SODIUM; DRONABINOL;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DEGRADATION; DRUG IDENTIFICATION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; RATE CONSTANT; RETENTION TIME; SIMULATION; STOMACH JUICE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY;

EID: 85013154348     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2015.0004     Document Type: Article

References (36)

1. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4:e0022.
2. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791-802.
3. El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav. 2010;95:434-442.
4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
5. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids. 2002;121:35-43.
6. Gaoni Y, Mechoulam R. Concerning the isomerization of D1 to D6-tetrahydrocannabinol. J Am Chem Soc. 1966;88:5673-5675.
7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199-215.
8. Abramovici H. Cannabis (marihuana, marijuana) and the cannabinoids. Available at www.hc-sc.gc.ca/dhp-mps/marihuana/med/infoprofeng. php (accessed February 16, 2016).
9. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162-171.
10. Kraft B. Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology. 2012;89:237-246.
11. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8:403-421.
12. Mackie K. Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol. 2008;286:S60-S65.
13. Maccarrone M, Gasperi V, Catani MV, et al. The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr. 2010;30:423-440.
14. Serrano A, Parsons LH. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther. 2011;132:215-241.
15. Battista N, Di Tommaso M, Bari M, et al. The endocannabinoid system: an overview. Front Behav Neurosci. 2012;6:9.
16. Zhornitsky S, Potvin S. Cannabidiol in humans\-The quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5:529-552.
17. Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol. 2005;168:719-756.
18. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and anti-seizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332:569-577.
19. Roser P, Vollenweider FX, Kawohl W. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World J Biol Psychiatry. 2010;11:208-219.
20. Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. 2011;51:1054-1061.
21. Rock EM, Goodwin JM, Limebeer CL, et al. Interaction between nonpsychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl). 2011;215:505-512.
22. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175-185.
23. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515-527.
24. Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21:344-352.
25. Gupta S. Dr. Sanjay Gupta: It's time for a medical marijuana revolution. Available at www.cnn.com/2015/04/16/opinions/medical-marijuanarevolution-sanjay-gupta (accessed February 16, 2016).
26. Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52.
27. Devinsky O, Sullivan J, Friedman D, et al. Epidiolex (cannabidiol) in treatment-resistant epilepsy. Poster presented at 67th Annual Meeting of the American Academy of Neurology, April 18-25, 2015, Washington, DC.
28. Watanabe K, Itokawa Y, Yamaori S, et al. Conversion of cannabidiol to D9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicol. 2007;25:16-21.
29. United States Pharmacopeia. The dissolution procedure: development and validation. Chapter 1092. Available at www.usp.org/sites/default/ files/usp-pdf/EN/gc-1092.pdf (accessed February 12, 2016).
30. Marinol- (dronabinol) capsules. Prescribing information. Unimed Pharmaceuticals, Inc.; Marietta, GA, 2006. Available at www.rxabbvie.com/pdf/marinol-PI.pdf (accessed February 16, 2016).
31. Adams R, Pease DC, Cain CK, et al. Structure of cannabidiol. VI. Isomerization of cannabidiol to tetrahydrocannabinol, a physiologically active product. Conversion of cannabidiol to cannabinol. J Am Chem Soc. 1940;62:2402-2405.
32. Adams R, Cain CK, McPhee WD, et al. Structure of cannabidiol. XII. Isomerization to tetrahydrocannabinols. J Am Chem Soc. 1941;63:2209-2213.
33. Gaoni Y, Mechoulam R. The isomerization of cannabidiol to tetrahydrocannabinols. Tetrahedron. 1966;22:1481-1488.
34. Gong H Jr., Tashkin DP, Simmons MS, et al. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther. 1984;35: 26-32.
35. Bansal D, Azad C, Kaur M, et al. Adverse effects of antiepileptic drugs in North Indian pediatric outpatients. Clin Neuropharmacol. 2013;36: 107-113.
36. Anderson M, Egunsola O, Cherrill J, et al. A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ Open. 2015;5:e008298.